Effect of pentoxifylline on inflammatory markers in non-diabetic chronic kidney disease patients: A prospective, interventional, open label

doi:10.5527/wjn.120037

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 15, Issue 3

This Article

(18)

(17)

(0)

(745)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Nephrology

ISSN

2220-6124

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Randomized Controlled Trial

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Nephrol. Sep 25, 2026; 15(3): 120037
Published online Sep 25, 2026. doi: 10.5527/wjn.120037

Table 4 Relation between tumour necrosis factor-alpha and C-reactive protein with patients’ gender in both groups, mean ± SD

		Sex		t value¹	P value
		Male	Female	t value¹	P value
Group 1	TNF-α (ng/L) after 6 months	73.273 ± 23.230	82.000 ± 33.226	-0.703	0.490
Group 1	hs-CRP (mg/L) after 6 months	2.836 ± 0.707	3.430 ± 0.789	-1.818	0.085
Group 2	TNF-α (ng/L) after 6 months	63.000 ± 24.812	70.667 ± 27.848	-0.665	0.514
Group 2	hs-CRP (mg/L) after 6 months	2.642 ± 0.765	2.333 ± 0.721	0.937	0.361

¹Students’ t-test.

hs-CRP: High-sensitivity C-reactive protein; TNF-α: Tumour necrosis factor-alpha.

Full Size Table

Citation: Abd El Mobdy AH, Hebah HA, Ezzat MA, Eid Mohamed BA, Ahmed FA. Effect of pentoxifylline on inflammatory markers in non-diabetic chronic kidney disease patients: A prospective, interventional, open label. World J Nephrol 2026; 15(3): 120037
URL: https://www.wjgnet.com/2220-6124/full/v15/i3/120037.htm
DOI: https://dx.doi.org/10.5527/wjn.120037

Abd El Mobdy AH, Hebah HA, Ezzat MA, Eid Mohamed BA, Ahmed FA. Effect of pentoxifylline on inflammatory markers in non-diabetic chronic kidney disease patients: A prospective, interventional, open label. World J Nephrol 2026; 15(3): 120037 [PMID: 42626272 DOI: 10.5527/wjn.120037]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.